Summary:
- QureBio, a biopharmaceutical company in Shanghai, China, secured nearly CNY 100M in Series C1 funding led by Efung Capital.
- The company aims to use the funds to expedite clinical trials and advance its pipeline of new antibody therapeutics.
- QureBio specializes in developing bispecific and multispecific antibodies for oncology, autoimmune diseases, and inflammatory disorders.
Article:
QureBio Secures Significant Funding for Advancing Antibody Therapeutics
QureBio, a prominent biopharmaceutical company based in Shanghai, China, recently announced a substantial milestone in its journey towards developing innovative antibody therapeutics. The company successfully raised nearly CNY 100M in Series C1 funding, with Efung Capital leading the investment round. This significant financial boost is expected to accelerate QureBio’s ongoing clinical trials and further advance its pipeline of novel antibody-based treatments.
Established in 2017, QureBio has positioned itself as a key player in the realm of antibody and protein therapeutics, with a primary focus on creating bispecific and multispecific antibodies targeted at addressing critical medical needs in areas such as oncology, autoimmune diseases, and inflammatory disorders. The company has developed proprietary technology platforms for antibody discovery and engineering, allowing for the creation of a robust pipeline of drug candidates that hold immense promise in the healthcare landscape of both China and beyond.
Key developments within QureBio’s pipeline include the progression of notable candidates such as Q-1802, a Claudin18.2/PD-L1 bispecific antibody that has received regulatory clearance for clinical trials in both China and the United States. Additionally, Q-1801, a SIRPα/PD-L1 bispecific antibody, has obtained clinical trial approvals and is on the brink of commencing clinical studies. Moreover, the company’s innovative PD-1 Antibody-Cytokine Fusion Candidate, a fusion protein with dual functions as a PD-1 checkpoint inhibitor and cytokine modulator, showcases a promising therapeutic window and seeks collaborations to expedite its global development.
With a clear focus on advancing the field of antibody therapeutics and addressing unmet medical needs, QureBio’s recent funding milestone signifies a pivotal moment in its journey towards bringing impactful treatments to patients worldwide. The company’s commitment to innovation and scientific excellence underscores its position as a frontrunner in the biopharmaceutical landscape, poised to make significant contributions to healthcare advancements in the near future.
Source: FinSMEs, 05/06/2025
